Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group

Bone Marrow Transplantation volume 35, pages 1011–1018 (2005)Cite this article

Summary:

A total of 155 patients with acute myeloid leukemia (AML) received hematopoietic stem cell transplants from unrelated donors after standard conditioning. Clinical outcome after the use of two different antithymocyte globulins for the prevention of graft-versus-host disease (GvHD) was analyzed in a retrospective study as follows: rabbit ATG (Thymoglobulin Sangstat/Genzyme, n=49, median age 42 years, 53% in CR, further ATG-S); rabbit ATG (ATG-Fresenius, n=38, median age 42 years, 58% in CR, further ATG-F) or no ATG (n=68, median age 36 years, 55% in CR). The groups were comparable regarding disease status at transplant, age, CMV status and cytogenetics. Grade III–IV acute GvHD was found in 15% in the ATG and 27% in the no ATG group (P=0.44). The most important independent risk factors for chronic GvHD (cGvHD) were the use of ATG, disease status at transplant and conditioning. cGvHD developed significantly more frequently in no ATG group. With the median follow-up of 34 months, the 5-year survival is 42% for those transplanted in CR. To conclude, these data demonstrate that the transplants performed in CR, with ATG, are associated with a good outcome, low incidence of cGvHD and no increase of relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Sierra J, Storer B, Hansen JA et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397–404.

    Article  CAS  PubMed  Google Scholar 

  2. Gratwohl A, Baldomero H, Horisberger B et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002; 100: 2374–2386.

    Article  CAS  PubMed  Google Scholar 

  3. Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching and marrow cell dose. Blood 1997; 89: 4226–4235.

    CAS  PubMed  Google Scholar 

  4. Hows J, Bradley B, Gore S et al. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371–380.

    CAS  PubMed  Google Scholar 

  5. Finke J, Schmoor C, Lang H et al. Matched and mismatched allogeneic stem cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 2003; 21: 506–513.

    Article  PubMed  Google Scholar 

  6. Zander AR, Zabelina T, Kröger N et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999; 23: 889–893.

    Article  CAS  PubMed  Google Scholar 

  7. Byrne JL, Stainer C, Culli G et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukemia. Bone Marrow Transplant 2000; 25: 411–417.

    Article  CAS  PubMed  Google Scholar 

  8. Bacigalupo A, Lamparelli T, Bruzzi P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.

    Article  CAS  PubMed  Google Scholar 

  9. Bloomfield CD, Lawrence D, Byrd JC et al. Frequency of prolonged remission duration after high-dose cytarabin intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173–4179.

    CAS  PubMed  Google Scholar 

  10. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  11. Dastique N, Payen C, Lafage-Pochitaloff M et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia 1995; 9: 1491–1498.

    Google Scholar 

  12. Schoch C, Haase D, Haferlach T et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 1996; 10: 1288–1295.

    CAS  PubMed  Google Scholar 

  13. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia. A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  14. Ottinger HD, Albert E, Arnold R et al. German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells. Bone Marrow Transplant 1997; 20: 101–105.

    Article  CAS  PubMed  Google Scholar 

  15. Przepiorka D, Weisdorf D, Martin P et al. Meeting report. Consensus conference on acute GvHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  16. Sullivan KM . Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation. Blackwell Science: Oxford, 1999, pp 515–536.

    Google Scholar 

  17. Basara N, Kiehl MG, Fauser AA . New therapeutic modalities in the treatment of graft-versus-host disease. Crit Rev Oncol/Hematol 2001; 38: 129–138.

    Article  CAS  Google Scholar 

  18. Ringden O, Remberger M, Ruutu T et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis and alopecia with busulfan versus total body irradiation: long term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood 1999; 93: 2196–2201.

    CAS  PubMed  Google Scholar 

  19. Clift R, Goldman JM, Gratwohl A, Horowitz M . Proposal for standardized reporting of bone marrow transplantation for leukemia. Bone Marrow Transplant 1989; 4: 445–448.

    CAS  PubMed  Google Scholar 

  20. Kaplan EL, Meier P . Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  21. Cox DR . Regression models and life tables. J R Stat Soc 1972; 34: 187–202.

    Google Scholar 

  22. Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496–509.

    Article  Google Scholar 

  23. Chiodi S, Spinelli S, Ravera G et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000; 110: 614–619.

    Article  CAS  PubMed  Google Scholar 

  24. Preville X, Nicolas L, Flacher M, Revillard J . A Quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulins (rATG). J Immunol Methods 2000; 245: 45–54.

    Article  CAS  PubMed  Google Scholar 

  25. Remberger M, Svahn B-M, Hentschke P et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823–830.

    Article  CAS  PubMed  Google Scholar 

  26. Remberger M, Svahn B-M, Mattsson J, Ringden O . Thymoglobulin as part of conditioning in unrelated donor allogeneic stem cell transplantation* A dose-finding study. Bone Marrow Transplant 2004: (Suppl. 1): 278a.

  27. Schleuning M, Günther W, Tischer J et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003; 32: 243–250.

    Article  CAS  PubMed  Google Scholar 

  28. Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999; 94: 455–464.

    CAS  PubMed  Google Scholar 

  29. Remberger M, Ringden O, Blau IW et al. No difference in graft-versus-host disease, relapse and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739–1745.

    Article  CAS  PubMed  Google Scholar 

  30. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    Article  CAS  PubMed  Google Scholar 

  31. Preville X, Flacher M, Le Mauff B et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460–468.

    Article  CAS  PubMed  Google Scholar 

  32. Mueller TF . Thymoglobulin: an immunologic overview. Curr Opin Organ Transplant 2003; 8: 305–312.

    Article  Google Scholar 

  33. Pistillo MP, Tazzari PL, Bonifazi F et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. Transplantation 2002; 73: 1295–1302.

    Article  CAS  PubMed  Google Scholar 

  34. Revillard JP, Bonnefoy-Bérard N, Préville X et al. Immunopharmacology of Thymoglobulin. Graft 1999; 2 (Suppl.): 6–9.

    Google Scholar 

  35. Genestier L, Fournel S, Flacher M et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360–2368.

    CAS  PubMed  Google Scholar 

  36. Michallet M-C, Saltel F, Preville X et al. Cathepsin-B-dependent apoptosis triggerd by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood 2003; 102: 3719–3726.

    Article  CAS  PubMed  Google Scholar 

  37. Baurmann H, Judith D, Zey C et al. Antithymocyte globulin Fresenius or SangStat (Genzyme) as part of the conditioning for unrelated donor HSCT: emerging differences in post-transplant immune reconstitution. Bone Marrow Transplant 2004; 33 (Suppl. 1): O299.

    Google Scholar 

  38. Farag SS, Fehniger TA, Ruggeri L et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935–1947.

    Article  CAS  PubMed  Google Scholar 

  39. Locatelli F, Velardi A, Giebel S . Response: the role of NK alloreactivity on the outcome of patients who received transplants from unrelated volunteers is influenced by different disease- and transplant-related variables. Blood 2004; 103: 2862.

    CAS  Google Scholar 

  40. Blaise D, Maraninchi D, Michallet M et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001; 97: 3669–3671 (letter to the editor).

    Article  CAS  PubMed  Google Scholar 

  41. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the nordic bone marrow transplantation group. Blood 1994; 83: 2723–2730.

    CAS  PubMed  Google Scholar 

  42. Socie G, Clift RA, Blaise D et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569–3574.

    Article  CAS  PubMed  Google Scholar 

  43. Bloomfield CD, Lawrence D, Byrd JC et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173–4179.

    CAS  PubMed  Google Scholar 

  44. Schleuning M, Kaltenhäuser J, Heshmat M et al. The influence of ATG source on the outcome after unrelated transplants for chronic phase CML – a single-centre experience. Bone Marrow Transplant 2004; 33 (Suppl. 1): O357.

    Google Scholar 

  45. Kolb H-J, Schmid Ch, Barrett AJ, Schendel DJ . Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767–776.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein, Germany

    N Basara & A A Fauser

  2. Deutsche Klinik für Diagnostik, BMT Unit, Wiesbaden, Germany

    H Baurmann, A Yaman & R Schwerdtfeger

  3. III Medical Clinic, Gutenberg University, Mainz, Germany

    K Kolbe, A Burchardt & C Huber

  4. ALWP EBMT Office, Paris, France

    M Labopin

Authors
  1. N Basara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Baurmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Kolbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Yaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Burchardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A A Fauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Schwerdtfeger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Basara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basara, N., Baurmann, H., Kolbe, K. et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 35, 1011–1018 (2005). https://doi.org/10.1038/sj.bmt.1704957

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704957

Keywords

This article is cited by

Search

Advanced search

Quick links